The Technical AnalystExchange: Oslo Stock Exchange Sector: Healthcare Industry: Biotechnology
Nykode Therapeutics AS Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.98% NOK13.37
/ 30 apr 2024 @ 10:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 365.92 mill |
| EPS: | -1.320 |
| P/E: | -10.13 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 326.55 mill |
| Avg Daily Volume: | 1.091 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.13 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -10.13 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
NOK 12.63 - 14.11 ( +/- 5.55%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
-8.00
Sell
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | NOK13.37 (0.98% ) |
| Volume | 0.318 mill |
| Avg. Vol. | 1.091 mill |
| % of Avg. Vol | 29.18 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NYKD.OL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Apr 5 - 03:34 | buy | NOK14.04 | N/A | Active |
|---|
NYKD.OL
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.